4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Rhythm Pharmaceuticals, Inc. (RYTM) operates in the Biotechnology industry and is headquartered in Boston, United States with about 414 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, RYTM reported $190M in revenue and ($196M) in net income.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Interactive charts & full statements → Open the RYTM valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $190M | $130M | $77M | $24M |
| Gross Profit | $170M | $117M | $68M | $22M |
| Operating Income (EBIT) | ($192M) | ($266M) | ($184M) | ($179M) |
| Net Income | ($196M) | ($261M) | ($185M) | ($181M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $60M | $57M | $51M | $48M | $33M | — |
| Gross Profit | $53M | $52M | $46M | $43M | $29M | — |
| Operating Income (EBIT) | ($52M) | ($47M) | ($53M) | ($45M) | ($47M) | — |
| Net Income | ($56M) | ($48M) | ($53M) | ($47M) | ($50M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $480M | $392M | $333M | $382M | — |
| Total Liabilities | $210M | $228M | $163M | $118M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RYTM viewer.
About TickerBase · Data methodology & sources